Dear colleagues and friends,

The first Post-Chicago Meeting on Melanoma / Skin Cancer took place 2011. In 2017, the meeting has attracted more than 600 participants from almost 35 countries. The interactive congress offers a comprehensive overview on all new developments in melanoma diagnostics and therapy and a direct communication with the world´s leading experts in these fields.

The aim of the Interdisciplinary Global Conference on News in Melanoma / Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.

International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.

Please join us for this event and submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you in Munich in June 2018!

Axel Hauschild, MD          Claus Garbe, MD
Congress Presidents


Sanjiv Agarwala, Bethlehem, USA
Petr Arenberger, Prague, Czech Republic
Paolo Ascierto, Naples, Italy
Jürgen Becker, Essen, Germany
Carola Berking, Munich, Germany
Christian Blank, Amsterdam, The Netherlands
Lieve Brochez, Ghent, Belgium
Matilda Bylaité-Bucinskiene, Vilnius, Lithuania
Reinhard Dummer, Zurich, Switzerland
Thomas Eigentler, Tübingen, Germany
Andrea Forschner, Tübingen, Germany
Claus Garbe, Tübingen, Germany
Christoffer Gebhardt, Hamburg, Germany
Jean Jacques Grob, Marseille, France
Ralf Gutzmer, Hannover, Germany
Axel Hauschild, Kiel, Germany
Lucie Heinzerling, Erlangen, Germany
Christoph Höller, Vienna Austria
Katharina Kähler, Kiel, Germany
Lidija Kandolf-Sekulovic, Belgrade, Serbia
Roland Kaufmann, Frankfurt, Germany
Felix Kiecker, Berlin, Germany
Jennifer Landsberg, Bonn, Germany
James Larkin, London, United Kingdom
Celeste Lebbé, Paris, France
Carmen Loquai, Mainz, Germany
Paul Lorigan, Manchester, United Kingdom
Friedegund Meier, Dresden, Germany
Olivier Michielin, Lusanne, Switzerland
Zeljko Mijuskovic, Belgrade, Serbia
Peter Mohr, Buxtehude, Germany
David Moreno-Ramirez, Sevilla, Spain
Judit Oláh, Szeged, Hungary
Klaus Pantel, Hamburg, Germany
Ketty Peris, Rome, Italy
Annette Pflugfelder, Tübingen, Germany
Caroline Robert, Paris, France
Dirk Schadendorf, Essen, Germany
Bastian Schilling, Würzburg, Germany
Alexander Stratigos, Athens, Greece
Ricardo Vieira, Coimbra, Portugal
Jennifer Wargo, Houston, USA
Jeffrey Weber, New York, USA
Benjamin Weide, Tübingen, Germany
Iris Zalaudek, Trieste, Italy


There will be a Speaker’s Preview Room provided for all speakers. The Speaker’s Preview Room is located on the ground floor in room R3.

Opening hours

Thursday, June 28:08:00-19:00
Friday, June 29:07:00-17:30

The following facilities will be provided in the room:

  • computers (operating system Windows) to review, alter and upload the presentations to the server
  • support by technical staff is available

The conference staff will transfer the presentation to the corresponding Session Rooms. The presentations should be handed in to the Speaker’s Preview Room at least two hours before the session. All speakers will easily find their presentations on the preview monitor on the lectern in the Royal Ballroom or on the laptop in R1+R2.


  • Deadline Abstract Submission: May 1, 2018.
  • Notification of Acceptance of Abstracts: May 14, 2018

All those interested in presenting abstracts at the 8th European Post-Chicago Melanoma Meeting are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the Free Communications Sessions. The best oral presentation and the best poster on display will be awarded during the congress with an award of 500€ each. The acceptance of an abstract does not include the congress registration.

Abstract Writing:

  • The structured abstracts should be written according to the rules of the Chicago congress: Up to ten authors can be listed. Please give only the first letters of prenames with a dot.
  • The institutions shall be listed in the order of the authors without links to the authors. Please give city and country of the institutions.
  • Please indicate the preferred type of presentation (oral or poster).
  • The text of the structured abstract (Background, Methods, Results, Conclusions) shall not exceed 2500 letters including blanks.
  • It is acceptable to include a table as part of the abstract.
  • Please format the abstract as shown in the example below, please use Arial 10.
  • All accepted abstracts will be published in the digital “Book of Abstracts” which can be downloaded after the congress here. Abstracts will not be edited by the Congress Secretariat prior to publication.


Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. C. Garbe, A. Romanini, G. Spitaleri, L. Giovannoni, L. Zardi, D. Neri, A. Shaw, H. D. Menssen, F. deBraud, T. K. Eigentler; University of Tuebingen, Tuebingen, Germany; Santa Chiara University Hospital, Pisa, Italy; European Institute of Oncology, Milan, Italy; Philogen SPA, Siena, Italy; Istituto Giannina Gaslini, Genoa, Italy; Swiss Federal Institute of Technology, Zurich, Switzerland; Bayer HealthCare Pharmaceuticals, Montville, NJ


L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format directed against the ED-B domain of fibronectin and the human cytokine interleukin-2 (IL2). The recommended dose (RD) for monotherapy of advanced solid cancer patients was established to be 22.5 Mio IU IL2 equivalent on day 1, 3, and 5 of a 21-day cycle. Here we report clinical results of the dose escalation part of a phase I/II study assessing L19-IL2 in combination with DTIC chemotherapy in metastatic melanoma patients.


L19-IL2 was administered as an i.v. infusion at doses of 10 (n=3), 15 (n=3) and 22.5 MioIU IL2 equivalent dose (n=4) on days 1, 3 and 5 every 21 days in combination with DTIC 1000 mg/m2 on Day 1 for up to 6 treatment cycles. Serum samples for PK evaluation and induction of human antifusion antibodies to L19 (HAFA) were collected. Flow cytometry (T and NK/B cell panels) was performed. Data on safety and activity were evaluated using CTC v3.0 and RECIST criteria, respectively.


All 10 patients had progressive metastatic melanoma and the majority had already received prior systemic therapy. Median age at start of treatment was 62 years (52-74). There were no treatment related deaths and the treatment was well tolerated, details of CTC evaluation will be presented. The dose of 22.5 Mio IU day 1, 3, and 5 in combination with 1000 mg DTIC/m2 on day 1, repeated on day 22 was defined as the RD for up to 6 treatment cycles. 10 patients were evaluable for response. We observed 1 partial remission at the 15 Mio IL2 dose level after 4 treatment cycles. Immunophenotyping analysis showed transient stimulation of NK cells, T4 cells, and CTLs. Pharmacokinetic data will be presented.


L19-IL2 at a dose of 22.5 Mio IU IL2 equivalent on days 1, 3, and 5 of a 3-weekly schedule can be safely combined with standard DTIC in metastatic melanoma patients. Toxicity was manageable and reversible. Preliminary evaluation suggests clinical activity of the L19IL2/DTIC regimen in metastatic melanoma patients.